6533b85ffe1ef96bd12c12e3
RESEARCH PRODUCT
Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques.
Daniela Di LisiGiuseppina NovoGirolamo Mannosubject
medicine.medical_specialtyLongitudinal strainmedicine.medical_treatmentAntineoplastic Agents030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineInternal medicineNatriuretic Peptide BrainmedicineHumans030212 general & internal medicineSubclinical infectionChemotherapyCardiotoxicityEjection fractionbiologybusiness.industryCardiotoxicity GLS myocardial work myocardial functionCancer survivalStroke VolumeGeneral MedicineTroponinMagnetic Resonance ImagingCardiotoxicityPeptide FragmentsTroponinEarly DiagnosisEchocardiographybiology.proteinCardiologyCardiology and Cardiovascular MedicinebusinessBiomarkersdescription
In recent years, the cancer survival of patients has improved thanks to advances in the pharmacological field. In many guidelines, cardiotoxicity induced by anticancer drugs was defined as a reduction from baseline in the left ventricular ejection fraction (LVEF) assessed by echocardiography. It is known that LVEF is not a sensible parameter in the detection of cardiotoxicity. Therefore, a decrease from baseline in the global longitudinal strain (GLS) or troponins elevation is used to detect subclinical cardiotoxicity. LVEF and GLS as well as the increase in some biomarkers are influenced by loading conditions that are frequent during chemotherapy. Other parameters not influenced by loading conditions should be used in the early diagnosis of cardiotoxicity. The aim of this review is to delineate the role of current strategies used in the early diagnosis of cardiotoxicity and to identify new strategies that could have greater application in the future in cardioncology.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-06-01 | Current problems in cardiology |